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ABSTRACT: As a key player of the protein quality control network of the cell, the molecular chaperone Hsp70 inhibits the 
aggregation of the amyloid protein tau. To date, the mechanism of this inhibition and the tau species targeted by Hsp70 remain 
unknown. This is partly due to the inherent difficulty of studying amyloid aggregates because of their heterogeneous and transient 
nature. Here, we used ensemble and single-molecule fluorescence measurements to dissect how Hsp70 counteracts the self-
assembly process of K18 tau with the pathological deletion ∆K280. We found that Hsp70 blocks the early stages of tau aggregation 
by suppressing the formation of tau nuclei. Additionally, Hsp70 sequesters oligomers and mature tau fibrils with nanomolar affinity 
into a protective complex, efficiently neutralizing their ability to damage membranes and seed further tau aggregation. Our results 
provide novel insights into the molecular mechanisms by which the chaperone Hsp70 counteracts the formation, propagation and 
toxicity of tau aggregates.  
INTRODUCTION 
The aberrant aggregation of tau into intracellular deposits is 
thought to play a key role in the pathogenesis of various 
human tauopathies including Alzheimer’s disease (AD)1. 
During disease, tau forms large intracellular aggregates termed 
neurofibrillary tangles, and their abundance and localization in 
the brain correlates with cognitive decline2,3. As part of the 
quality control machinery of the cell, molecular chaperones 
such as the highly abundant heat shock protein 70 (Hsp70) 
counteract the aggregation of amyloid proteins and target 
misfolded species for degradation.4 
Over the last few decades, a robust body of literature has 
provided evidence for an important role of Hsp70 in the 
pathogenesis of AD and other tauopathies, including the 
formation of a stable Hsp70-tau complex under conditions of 
cell stress,5–7 the regulation of tau degradation8,9 and the 
inhibition of tau aggregation by Hsp70.10–13 The inhibitory 
action by Hsp70 was found to be independent of ATP/ADP 
and co-chaperones.10–12 Further, hippocampal sections from 
AD patients show elevated Hsp70 levels as compared to age-
matched controls.13,14 These hippocampal sections have been 
found to be either immuno-positive for Hsp70 or for tau, 
suggesting that the presence of Hsp70 indeed leads to a local 
reduction of insoluble tau.14 Accordingly, induction or 
overexpression of Hsp70 in various cell lines leads to a 
reduction of insoluble and hyperphosphorylated tau inside 
cells and facilitates the association of tau with microtubules 
and microtubule polymerization.9,14,15 These findings illustrate 
the capacity of Hsp70 to prevent tau aggregation and target 
aberrant tau species for degradation. 
However, currently it is not known which molecular steps 
of tau aggregation are inhibited by Hsp70 and which tau 
species are targeted by the chaperone. This is partly owing to 
the difficulty of studying protein aggregates as they are highly 
heterogeneous in nature and can populate rare and transient 
species such as small soluble oligomers. Highly sensitive 
single-molecule fluorescence methods have previously been 
employed to overcome these limitations and to study 
amyloidogenic proteins and their interactions at the single 
aggregate level.16–24 This has recently allowed an in-depth 
characterization of the oligomerization and fibrillization 
kinetics of K18 tau (a short tau construct containing the four 
aggregation prone repeat regions) and its pathological mutants 
P301L tau and ∆K280 tau.25 Particularly the mutant ∆K280 
tau was shown to have a pronounced oligomerization phase, 
during which early oligomeric species are highly populated 
before the onset of fibrillization. Because of the well-defined 
aggregation kinetics of this tau version and the presence of 
two Hsp70 binding sites10 within K18 tau, we chose this 
construct to study how Hsp70 interacts with the different 
species formed during the aggregation of tau. We found that 
Hsp70 blocks the early stages of tau aggregation by 
suppressing the formation of small tau nuclei. Once tau fibrils 
are formed, they are sequestered with low nanomolar affinity 
(~20 nM) into a protective complex by Hsp70, neutralizing the 
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ability of tau to propagate by seeded aggregation. Finally, we 
also demonstrate that Hsp70 reduces the toxic properties of 
soluble tau oligomers with lipid membranes. Taken together, 
our results show how the chaperone Hsp70 counteracts the 
formation, propagation and toxicity of tau aggregates. 
RESULTS AND DISCUSSION 
Hsp70 is a sub-stoichiometric inhibitor of tau aggregation 
To confirm the inhibitory effect of Hsp70 on tau 
aggregation, the fibrillization of K18 ∆K280 tau was 
monitored in the absence and presence of Hsp70 using the 
reporter dye Thioflavin-T (ThT). ThT is a benzothiazole dye 
that exhibits enhanced fluorescence upon binding to beta-sheet 
rich amyloid fibrils. As expected, Hsp70 inhibited the 
aggregation of tau in a dose-dependent fashion when added to 
the aggregation mixture prior to the induction of aggregation 
(Figure 1a). To corroborate these findings, a sedimentation 
assay was used to measure the relative levels of soluble and 
insoluble K18 ∆K280 tau with increasing Hsp70 
concentration. In the absence of Hsp70, over 80% of protein 
was found in the pellet after 24 hours of aggregation. With 
increasing concentration of Hsp70, the relative amount of tau 
in the insoluble tau fractions decreased, and the majority of tau 
was detected in the supernatant (Figure 1b and c). 
We note here a discrepancy between the sedimentation 
assay and the ThT assay, with the latter showing similar 
fluorescence values after one day of aggregation for all four 
conditions. Therefore, we analyzed the composition of 
samples after 24 hours by total internal reflection fluorescence 
(TIRF) microscopy and transmission electron microscopy 
(TEM). By using the dye pentameric formyl thiophene acetic 
acid (pFTAA), which binds to beta-sheet rich aggregates 
similar to the dye ThT, we can readily detect single fibrils and 
mature oligomers by TIRF microscopy26,27. 
 
Figure 1 | Hsp70 inhibits tau aggregation in a sub-stoichiometric manner 
a) The extent of heparin induced K18 ∆K280 tau fibrillization, monitored by Thioflavin-T (ThT) fluorescence over the course of the 
aggregation reaction. Black line: tau only (10 µM); gray line: + 0.5 µM Hsp70 (1:20 Hsp70:tau); red line: + 2 µM Hsp70 (1:5 Hsp70:tau); 
blue line: + 10 µM Hsp70 (1:1 Hsp70:tau). N=3, error bars are s.e.m. 
b) Sedimentation assay: Soluble and insoluble K18 ∆K280 tau present after 24 h in the absence and presence of Hsp70. Representative 
SDS-PAGE analysis, coomassie staining. N=3.  
c) Relative protein levels in supernatant and pellet by densitometry of SDS-PAGE bands. N=3, error bars are s.e.m. 
d) The aggregates obtained at the end of the aggregation reactions visualized on a TIRF microscope (pFTAA staining) and by TEM. 
Representative images (N=3). Scale bars: TIRFM 10 µm, TEM 500 nm. 
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As evident from the TIRF images and electron micrographs, 
tau aggregates became smaller when aggregated with 
increasing Hsp70 concentrations, although the majority of 
aggregates still appeared to have high beta-sheet content, as 
evident by pFTAA staining. The majority of these small 
pFTAA-active aggregates remained in the supernatant during 
centrifugation at 16,000 g, explaining the discrepancy between 
the recorded ThT-kinetics and the pelleting assay (see Figure 
S1). At the highest Hsp70 concentration (1:1 tau:Hsp70), 
small oligomeric species were observed by TEM with around 
25 nm diameter. These species were still pFTAA-active but 
weaker, presumably due to their smaller size (see Figure 1d). 
The observation that tau aggregates appear smaller in the 
presence of Hsp70 indicates that the chaperone inhibits the 
elongation of tau aggregates. Therefore, we next set out to test 
this directly using kinetic measurements of elongation. 
Hsp70 inhibits elongation of tau 
To test whether Hsp70 inhibits the elongation of K18 
∆K280 tau fibrils, a seeding assay was performed using a high 
concentration of tau seeds. Under these conditions, the initial 
aggregation kinetics are determined purely by the elongation 
of existing seeds and thus the relative elongation rates k!!  for 
different samples can be extracted from fits of the initial 
aggregation rates28,29 (see supporting information). Here, tau 
seeds were prepared from a fibrillar tau sample and these were 
used to seed monomeric tau in the presence of varying Hsp70 
concentrations. The increase of fibril mass upon fibril 
elongation was monitored by ThT fluorescence. Indeed, the 
aggregation kinetics of tau were markedly slower in the 
presence of Hsp70 (Figure 2a). The relative elongation rate 
constants (k!! ) of tau seeds were then derived from linear fits 
of the initial aggregation kinetics (see Figure 2a insert). 
Plotting these constants as a function of Hsp70 concentration 
revealed a dose-dependent decrease of k!!   (Figure 2b), 
corroborating an inhibition of tau aggregate elongation by 
Hsp70.  
SmFRET shows inhibition of tau nucleation by Hsp70 
Next, we set out to test the effect of Hsp70 on the early 
stages of tau aggregation, specifically the formation of small 
oligomeric species. For this purpose, we employed a single-
molecule Foerster Resonance Energy Transfer (smFRET) 
assay, which is able to detect even the smallest protein 
aggregates such as dimers or trimers in an excess of 
monomers21. For this assay, a K18 ∆K280 tau sample was 
separated into two aliquots and labeled with two different 
fluorophores, a FRET donor (Alexa Fluor 488) and a FRET 
acceptor (Alexa Fluor 647). These monomeric versions tau-
AF488 and tau-AF647 were then combined at equal amounts 
and co-aggregated. In order to monitor the formation of 
oligomers, the mixture was diluted to picomolar concentration 
and analyzed on a dual-color confocal microscope. Single 
dual-labeled aggregates moving through the confocal volume 
one-by-one give rise to single FRET events. These can readily 
be counted and analyzed with regards to their approximate 
size and structure of the aggregate based on their intensity and 
FRET efficiency respectively (Figure 3a). This assay was 
conducted in the absence and presence of increasing Hsp70 
concentrations to assess the effect of the chaperone on the 
nucleation and aggregation of tau. 
When K18 ∆K280 tau (5 µM tau-AF488 and 5 µM tau-
AF647) was aggregated in the absence of Hsp70, the protein 
rapidly nucleated into a population of oligomers after the 
addition of heparin (Figure 3b, black dots). The maximum 
number of oligomers was observed after less than one hour, 
followed by a steady decline showing the transient nature of 
these oligomers. Strikingly, in the presence of Hsp70 the 
number of early oligomers was strongly reduced in a dose-
dependent manner with a 1:5 sub-stoichiometric concentration 
of Hsp70 leading to a reduction of early oligomeric species by 
approximately 50% (Figure 3b, colored dots). This was 
particularly evident for small oligomeric species (apparent size 
< 10mer), which  were depleted at the early time points (0-2 h) 
(see Figure 3c). 
 
Figure 2 | Hsp70 inhibits tau elongation 
a) Seeded aggregation of K18 ∆K280 tau in the presence of Hsp70. The increase of relative aggregate mass upon addition of free 
monomers (10 µM) to existing seeds (10 µM) was measured over time by ThT fluorescence and normalized. Black line: tau only; gray 
line: + 0.5 µM Hsp70 (1:20 Hsp70:tau); red line: + 2 µM Hsp70 (1:5 Hsp70:tau); blue line: + 10 µM Hsp70 (1:1 Hsp70:tau). N=3, error 
bars were omitted for the sake of clarity; Insert: Representative linear fits of the initial aggregation rate to derive the elongation rate of 
seeds as a function of Hsp70 concentration. 
b) Relative elongation rates (𝑘!! ) of tau seeds as a function of Hsp70 concentration. Error bars: st. dev. of experimental repeats. Statistical 
test: One-way ANOVA; ** signifies p ≤ 0.01, **** p ≤ 0.0001
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This marked reduction of early oligomeric species in the 
presence of the chaperone strongly suggests that primary 
nucleation of K18 ∆K280 tau is inhibited by Hsp70. Notably, 
besides the suppression of nucleation, our smFRET data also 
showed a stabilization of a fraction of early tau oligomers in 
the presence of Hsp70 (see Figure 3b, 24h). 
The FRET efficiencies observed for tau oligomers did not 
change in the presence of the chaperone, indicating that no 
structural change is induced by Hsp70 (Figure 3d).  
 
Figure 3 | smFRET shows reduced number of nuclei in the presence of Hsp70. 
a) Typical smFRET spectrum obtained from dual-labeled protein aggregates on a confocal microscope. Single aggregates passing through 
the confocal volume gave rise to single FRET events which were quantified with regards to frequency, intensity and FRET efficiency. 
b) Evolution of K18 ∆K280 tau oligomers as a function of aggregation time measured by smFRET. Black: tau only, gray: 1:20 Hsp70:tau, 
red 1:5 Hsp70:tau, blue 1:1 Hsp70:tau. N=3, error bars are s.e.m. 
c) Apparent sizes of oligomers formed in the absence and presence of Hsp70 after 45 minutes of aggregation. Sizing reveals a strong 
decrease in the population of small nuclei formed in the first hour of aggregation. 
d) FRET efficiencies of oligomers in the absence and presence of Hsp70 after 45 minutes of aggregation. Black: tau only, gray: 1:20 
Hsp70:tau, red 1:5 Hsp70:tau, blue 1:1 Hsp70:tau. 
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Affinity of Hsp70 for different tau aggregates 
The data presented above suggest that Hsp70 binds and 
stabilizes different K18 ∆K280 tau aggregates such as 
oligomers and fibrils. In order to characterize this property in 
more detail, e.g. the binding stoichiometry and affinity, Hsp70 
was labeled with Alexa Fluor 405 (AF405). Then co-
localization studies with different tau species were performed 
on a TIRF microscope. First, the binding of Hsp70-AF405 to 
labeled tau oligomers was assessed (1:5 Hsp70:tau 
stoichiometry). For TIRF imaging, the oligomeric sample was 
diluted and adsorbed onto a cover slide, allowing the 
visualization of individual dual-labeled oligomers. Hsp70-
AF405 fluorescence also concentrated around these oligomers, 
despite incubating the sample at the exceedingly low protein 
concentrations needed for single-molecule imaging 
(picomolar). This demonstrates the high kinetic stability of the 
Hsp70-tau oligomer complex (Figure 4a, middle panel, 
arrows). By contrast, the level of co-localization of Hsp70 
incubated with tau monomers was negligible under these 
conditions, suggesting rapid complex dissociation (see Figure 
4a, top panel, arrows). Finally, binding of Hsp70 to mature tau 
fibrils was assessed. Again, the majority of fibrillar tau 
aggregates co-localized with Hsp70, suggesting that Hsp70 
also forms a stable complex with tau fibrils (see Figure 4a 
bottom panel, arrows). 
In order to test the affinity of Hsp70 to different K18 ∆K280 
tau aggregates in a more quantitative manner, saturation 
binding assays were performed under pseudo-equilibrium 
conditions using our smFRET assay (see supporting 
information for more details). This time, K18 ∆K280 tau-
AF488 was used as a FRET donor and Hsp70 labeled with 
AF647 as a FRET acceptor (see Figure 4b). First, increasing 
amounts of Hsp70-AF647 were added to tau-AF488 oligomers 
and the association of the two proteins was measured for each 
concentration. Notably, the single-molecule resolution of our 
approach allowed us to assess the binding affinities of Hsp70 
to tau oligomers of different sizes. The size of an aggregate 
was estimated based on the fluorescence intensity emitted by 
the complex21. Importantly, this approach is an approximation 
which is limited by several factors such as fluorescence 
quenching and the non-homogenous illumination intensity of 
the confocal volume. To take this into account, the oligomer 
sizes shown here are given as apparent oligomer sizes. The 
saturation binding curves and respective dissociation constants 
(Kd) obtained for oligomers of different sizes are shown in 
Figure 4c-d. These show that the affinity of Hsp70 increases 
as a function of oligomer size with an apparent Kd around 170 
nM for large oligomers (10-mers and higher). 
Finally, the same binding assay was performed with a 
fibrillar tau sample to assess whether the binding affinity to 
fibrils follows this trend or is less tight as previously 
reported12. The binding curve obtained for tau fibrils was 
markedly shifted towards lower Hsp70 concentrations and the 
resulting Kd value obtained for the binding of Hsp70 to 
fibrillar tau (19 ± 5 nM) was an order of magnitude lower than 
the one obtained for large oligomers (Figure 4c-d). These 
results demonstrate that the apparent binding affinity of Hsp70 
to K18 ∆K280 tau aggregates increases as a function of 
aggregate size. 
Stoichiometry of Hsp70-binding to tau aggregates 
Next, we studied the binding stoichiometry of Hsp70 to tau 
oligomers based on our single-molecule data. First, we 
analyzed the apparent number of Hsp70 molecules (in 
multiples of monomer fluorescence intensities) bound to each 
tau oligomer from our TIRF images. This revealed a linear 
correlation between the size of the tau oligomer and the 
number of Hsp70 molecules bound (see Figure S3a). At the 
concentrations used for our co-localization study, i.e. 1:5 
Hsp70:tau ratio, the average binding stoichiometry was one 
Hsp70 molecule per two tau monomers in an oligomer (see 
Figure S3b). To assess how this ratio changes as a function of 
Hsp70 concentration, we examined the FRET efficiencies 
obtained during the saturation binding smFRET experiment. If 
one assumes that the orientation of acceptor molecules to 
donor molecules (binding mode of Hsp70 molecules to tau 
aggregates) does not change as a function of Hsp70 
concentration, the FRET efficiency measured for a tau-Hsp70 
complex effectively reports on the number of acceptors 
(Hsp70 molecules) bound to the donor (tau) (see schematic 
representation in Figure S3c). Indeed, the FRET efficiency of 
tau-aggregate complexes increased from around 0.15 at 10 nM 
Hsp70 to 0.65 at 1000 nM Hsp70 (concentration of tau 
aggregates in monomer units ≈ 100 nM), indicating that tau 
aggregates become increasingly decorated by Hsp70 
molecules. At high acceptor concentrations the FRET 
efficiency dropped, potentially due to non-specific binding or 
fluorescence quenching. Notably, the FRET efficiencies of 
Hsp70 binding to oligomers and fibrils did not differ 
markedly, indicating a similar mode of binding and surface 
density of Hsp70s (see Figure S3d).  
Hsp70 prevents tau oligomer toxicity 
Tau oligomers are known to impair the integrity of artificial 
lipid bilayers.30 The high-affinity binding of Hsp70 to K18 
∆K280 tau oligomers found here could serve as a mechanism 
to counteract such harmful surface interactions with 
membranes. In order to test this hypothesis, a single-vesicle 
permeabilization assay was employed which allows us to 
study the ability of aggregates to permeabilize membranes.31 
For this assay, lipid vesicles were loaded with Cal-520, a dye 
exhibiting increased fluorescence upon binding to Ca2+-ions. 
These vesicles were then immobilized onto a glass surface and 
incubated with the Ca2+-containing buffer L-15. Agents which 
are able to permeabilize the membrane of vesicles cause an 
influx of Ca2+-ions into the vesicles, leading to an increase in 
fluorescence intensity in those vesicles which can readily be 
detected on a TIRF microscope (see Figure 5a for a 
schematic). When vesicles were treated with 10 nM K18 
∆K280 tau oligomers, a strong influx of Ca2+ ions into the 
vesicles was observed (75% influx compared to the positive 
control ionomycin) (Figure 5b,c). This finding demonstrates 
that tau oligomers are indeed able to permeabilize lipid 
membranes as previously observed by Flach et al.30 At the 
same concentration, monomeric tau showed little effect on the 
vesicles (< 20% influx). When tau was oligomerized in the 
presence of Hsp70, the previously observed leakage of Ca2+ 
into the vesicles by tau oligomers was strongly reduced to less 
than 35% Ca2+-influx, corresponding to 50% of the initial 
oligomer response (see Figure 5c). This was also the case 
when Hsp70 was added to preformed tau oligomers just before 
the measurement (see Supporting Figure 4). These data show 
that Hsp70 neutralizes the ability of K18 ∆K280 tau oligomers 
to perturb lipid bilayers and suggest that tau toxicity could 
potentially be mitigated by acute upregulation or induction of 
Hsp70. 
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Figure 4 | Hsp70 affinity to K18 ∆K280 tau aggregates 
a) The binding of Hsp70-AF405 to different tau species was tested by TIRF microscopy. Representative images are shown (N=3.) Top 
panel: monomeric tau-AF488 incubated with Hsp70-AF405 under non-aggregating conditions. Middle panel: tau oligomers (tau-
AF488/AF647 co-aggregates) aggregated in the presence of Hsp70-AF405. Bottom panel: tau fibrils (pFTAA stain) incubated with 1.98 
µM unlabeled Hsp70 and 0.02 µM Hsp70-AF405. Arrows: co-localization of tau species with Hsp70. Scale bar 10 µm, inserts 2 µm. 
b) Schematic of binding assays performed: Tau-AF488 aggregates were kept at a constant concentration and increasing amounts of Hsp70-
AF647 were added until binding saturation was reached. The association between tau-AF488 and Hsp70-AF647 was measured by 
smFRET (AF488: donor, AF647: acceptor). 
c) Saturation binding curves obtained by adding increasing concentrations of Hsp70-AF647 to tau-AF488 aggregates. N=3, error bars are 
st. dev. Lines: fits. 
d) Dissociation constants extracted from fits shown in c. Error bars are st. dev. 
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Figure 5 | Hsp70 counteracts the ability of K18 ∆K280 tau aggregates to permeabilize the membrane 
a) Schematic of the membrane disruption assay. Single Cal520 filled vesicles are immobilized onto a glass cover slide. Addition of agents, 
which are able to disrupt the membrane of the vesicles leads to an influx of Ca2+-ions from the buffer into these vesicles. The resulting 
increase of fluorescence intensity in each vesicle is detected on a TIRF microscope. 
b+c) Hsp70 neutralizes the ability of K18 ∆K280 tau oligomers to impair lipid membranes. To test the effect of tau species - present at 
different times of the aggregation reaction - on membranes, either 10 nM monomeric tau, oligomeric tau or Hsp70-tau oligomer complexes 
were added to the lipid vesicles. Membrane disruption was measured by an increase of fluorescence intensity in each vesicle. Ionomycin 
was used as a positive control to normalize the data (100% Ca2+ influx). N=4, error are s.e.m. b) Representative images (N=4). Scale bar 5 
µm. c) Data from four independent experiments. Statistical test: One-way ANOVA; **** signifies p ≤ 0.0001. 
Summary: Mechanism of aggregation inhibition by Hsp70 
In the last few decades, it has become clear that Hsp70 is a 
key regulator of tau aggregation and turnover.32 However, 
mechanistic details on how Hsp70 blocks tau aggregation, 
such as the microscopic steps inhibited and the preferred target 
species of Hsp70, remain unknown. Here, we used highly 
sensitive single-molecule methods to study the interaction of 
Hsp70 with the different species on the aggregation pathway 
of tau. Using the well-studied tetrapeptide repeat tau construct 
K18 ∆K280, which contains the core region of mature tau 
filaments33,34 and two Hsp70 binding sites,10 we showed that 
Hsp70 blocks both the nucleation and - more efficiently – the 
elongation of tau by sequestering aggregates efficiently into a 
tight complex. 
Protective sequestration of tau monomers 
In the nucleation-conversion model of protein aggregation, 
which was recently shown to be applicable to K18 tau and the 
K18 mutant studied here25, small oligomeric nuclei are formed 
during the early phase of aggregation, a fraction of which will 
convert to growth competent species and elongate by 
monomer addition. The remaining oligomers are in 
equilibrium with the monomers and will therefore dissociate 
over time. Based on the low affinity of Hsp70 to monomeric 
tau (micromolar Kd of Hsp70 to 0N4R tau monomers7,35), one 
would expect only a weak inhibition of the nucleation process 
by Hsp70 present at micromolar concentrations in our 
aggregation reactions. This is consistent with our single-
molecule data, showing an inhibition of nucleation only at the 
two highest Hsp70 concentrations tested. Notably, we found 
that Hsp70 stabilized a fraction of the oligomers present at the 
early stages of the aggregation process. We observed no 
change in FRET efficiencies of aggregates in the presence of 
Hsp70, suggesting that Hsp70 does not induce off-pathway tau 
species as observed for Aβ36 and polyglutamine proteins.37 
The inhibitory action of Hsp70 on monomeric tau is likely a 
relevant factor in vivo, as the intracellular concentrations of 
both proteins are in the micromolar range, and thus the 
association of free cytosolic tau to Hsp70 is favored. Indeed, 
the constitutively expressed Hsp70 homolog Hsc70 was 
shown to rapidly engage tau monomers after destabilization of 
microtubules,15 showing the protective holdase nature of 
Hsp70 at the monomeric level (see Figure 6a). Notably, we 
could not observe direct binding of Hsp70 to tau monomers 
after diluting the complex to single-molecule concentrations 
(i.e. to picomolar protein concentrations), showing the 
transient nature of the Hsp70-tau monomer interaction. This 
finding is in agreement with a previous study which showed 
that the dissociation of tau monomers from the constitutively 
expressed variant Hsc70 occurs with an off-rate of 3.5 x 10-3 s-
1 (half-life ~3 minutes).10 
Inhibition of aggregate growth and propagation by Hsp70 
As demonstrated here, Hsp70 has a much higher affinity to 
aggregated tau species, with nanomolar Kd values for 
oligomers and fibrils. Therefore, the chaperone is likely to 
bind more tightly to growing aggregates, leading to an 
efficient inhibition of aggregate elongation. Consistent with 
this hypothesis, the elongation rate of tau seeds decreased 
significantly in the presence of Hsp70. Furthermore, 
increasing concentrations of Hsp70 in the reaction mixture led 
to a shortening of tau species observed after 24 hours of 
aggregation, whereby at the highest Hsp70 concentration (1:1 
tau:Hsp70) aggregates were found to be very small oligomeric 
species, presumably similar in size to initial converted 
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oligomer. A sequestration of growth competent seeds and the 
inhibition of their elongation by Hsp70 has also been observed 
for α-synuclein38 and the yeast prion Ure239, suggesting that 
this process is one the key mechanisms by which Hsp70 
counteracts the propagation of aggregates and could be the 
basis for the strong anti-aggregant effect of Hsp70 on tau and 
other proteins40 (see Figure 6b). In line with this hypothesis, 
hippocampal sections from AD patients are either 
immunoreactive for Hsp70 or fibrillar tau, suggesting that 
seeds can only grow and propagate in the absence of the 
chaperone.14 Despite this evidence for the protective effects of 
Hsp70, the role of Hsp70 in the propagation of pathological 
protein seeds remains unclear as the chaperone has described 
to be able to amplify aggregates by fragmentation40,41 and aid 
the secretion42,43 or uptake of seeds44,45.  
Binding mode of Hsp70 to tau aggregates 
Interestingly, when we tested the binding of Hsp70 to 
different tau species by smFRET, we found no difference in 
FRET efficiencies for oligomers and fibrils, suggesting a 
similar binding mode to these two aggregate species. This 
indicates that the affinity of the chaperone increases only as a 
function of aggregate size and that structural differences such 
as beta-sheet content are less critical for this interaction. Based 
on our single-molecule data and a previous report showing 
that Hsp70s occupy amyloid fibrils all along the fibril axis,41 
the apparent increase of affinity for larger aggregates is likely 
a result of an increased surface area on the aggregate which 
can be occupied by the chaperone. Since K18 tau lacks the 
long N- and C-terminal projection domains, it forms relatively 
compact fibrils.46,47 Given the lack of these relatively loose 
peptide stretches extending out from the fibril core and the 
relatively narrow substrate binding cleft of Hsp70, the tight 
binding to these dense filaments is noteworthy. This structural 
flexibility of Hsp70 for substrates of different levels of 
compaction (e.g. monomers vs. fibrils) shown here is in 
agreement with a recent study on the bacterial Hsp70 homolog 
DnaK showing the ability of DnaK to bind to unfolded, 
partially folded and near-native substrates.48 The high affinity 
of Hsp70 for tau aggregates may lay the basis for an efficient 
recruitment of factors initiating the degradation of tau such as 
the E3-ligase CHIP which was shown to be involved in tau 
turnover.8,9  
Hsp70 counteracts tau toxicity by direct binding 
Whilst fibrillar tau species have emerged as the key 
molecular species for seeding the aggregation of free 
monomeric tau in recipient cells,49 soluble oligomers of tau are 
thought to confer damage to cells and play an important role in 
neurodegeneration.50–52 Here, we used lipid vesicles to show 
that the tight sequestration of small tau oligomers by Hsp70 
abolishes their ability to confer damage to membranes. In a 
cell, this might serve to protect the cell membrane or 
membrane-rich organelles such as mitochondria or the 
endoplasmatic reticulum from toxic effects elicited by tau 
oligomers (Figure 6c). In a similar manner, the ability of tau 
aggregates to cross the cell membrane may be inhibited by 
Hsp70, hampering the trans-cellular propagation of tau (Figure 
6d). 
Conclusion 
In summary, we showed here that Hsp70 efficiently blocks 
the aggregation and toxicity of tau by sequestering tau 
aggregates with high affinity. This interaction may lay the 
basis for a subsequent clearance of harmful and seeding 
competent tau species, e.g. by proteasomal degradation or 
chaperone mediated autophagy53 or direct disaggregation of 
the aggregates by a Hsp70-driven disaggregase system41,54 
(Figure 6e). 
 
 
Figure 6 | Hsp70 holdase function blocks tau aggregation, propagation and toxicity 
a) Hsp70 inhibits the primary nucleation of tau by stabilizing monomeric and small oligomeric tau species. 
b) Hsp70 sequesters growth competent seeds with high affinity and inhibits their elongation by monomer addition. 
c) The binding of small oligomers by Hsp70 neutralizes their toxic properties such as membrane disruption. 
d) Hsp70 may inhibit the spreading of seeds by sequestering fibrils and inhibiting their release and uptake. 
e) The holdase function of Hsp70 may be the basis for the subsequent clearance of aberrant tau aggregates, e.g. via the proteasome, 
chaperone mediated autophagy (CMA) or direct disaggregation by Hsp70. 
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METHODS AND MATERIALS 
Chemicals. Alexa Fluor 488 C5 maleimide, Alexa Fluor 
647 C2 maleimide, Alexa Fluor 405 NHS ester and Alexa 
Fluor 647 NHS ester were purchased from Molecular Probes. 
Heparin (low molecular weight heparin) was obtained from 
Fisher Scientific UK. Ammonium acetate, thioflavin T (ThT) 
and dithiothreitol (DTT) were purchased from Sigma. pFTAA 
was a kind gift from Therese Klingstedt. 
Protein expression, purification and labeling. The K18 
ΔK280 tau construct used in this work contains a deletion of 
lysine 280 and both natural cysteine residues were mutated to 
alanine. It contains a cysteine mutation at position 260 used 
for the covalent attachment of the dyes as previously 
described25. The protein was kindly supplied by Professor St. 
George-Hyslop and labeled using Alexa Fluor 488 C5 or 647 
C2 maleimide according to established protocols. 
The expression and purification of Hsp70 was performed as 
previously described55. To label Hsp70, the protein was 
reacted with Alexa Fluor 405 NHS ester or Alexa Fluor 647 
NHS ester according to established protocols. The labelling 
efficiency was found to be 1.5 dyes/protein for Hsp70-AF405 
by measuring the UV absorbance at 401 nm (ɛAF405=34,000 M-
1 cm-1) and 1.3 dyes/protein for Hsp70-AF650 by measuring 
the UV absorbance at 650 nm (ɛAF650=250,000 M-1 cm-1) and 
the protein concentration determined by BCA assay.  
Tau aggregations and preparation of different tau species. 
All aggregation reactions were performed using 10 µM K18 
ΔK280 tau (unlabeled aggregates) or 5 µM ΔK280 tau-AF488 
+ 5µM ΔK280 tau-AF647 (dual-labeled aggregates) in 0.05 M 
ammonium acetate pH 7 containing 1 mM DTT. To start the 
aggregation, 0.01 mg ml-1 heparin was added to the samples 
(1:4 heparin:tau ratio). Samples were incubated at 37 °C 
without agitation for the indicated amounts of time. To obtain 
oligomeric tau, samples were incubated for 45 minutes and 
then transferred to an ice bath. The fraction of oligomers at 
this stage of the aggregation is around 10% as estimated by 
smFRET, i.e. the oligomer concentration is ~ 1 µM (in 
monomer starting concentration). To obtain fibrillar tau, 
samples were incubated for 24 hours. Under these conditions, 
the sample is predominantly fibrillar (≈90%) with negligible 
oligomer concentrations (see Figure 3b black dots, and Ref25). 
Monitoring fibril formation by thioflavin-T fluorescence. 
Hsp70 (0 µM, 0.5 µM, 2 µM or 10 µM) was added to K18 
ΔK280 tau (10 µM) in a microwell plate (Corning 96-well half 
area clear bottom) and 10 µM ThT was added. Fibrillation was 
monitored by excitation at 440 nm and collecting fluorescence 
at 480 nm using a BMG FLUOstar OPTIMA plate reader. 
Tau and Hsp70 pelleting assays. Hsp70 (0 µM, 0.5 µM, 2 
µM or 10 µM) was added to K18 ΔK280 tau (10 µM) in a 200 
µl PCR tube at 4° C. The aggregation was started by heparin 
addition and continued for the indicated amounts of time. To 
analyze the amount of soluble and insoluble protein after 
given periods of time, each mixture was centrifuged at 16,000 
g for 20 minutes. Supernatant and pellet fractions were then 
subjected to SDS-PAGE using 4-12% Bis-Tris gels (Bolt, 
Thermo Fisher Scientific) and protein bands stained with 
colloidal coomassie (BioRad). To quantify soluble and 
insoluble protein, densitometry was performed on the protein 
bands and protein levels were normalized to a non-aggregated 
control containing 10 µM ΔK280 tau only. 
Determining elongation rates of tau seeds in presence of 
Hsp70. Tau was fibrillated as described above. After 24 h, the 
fibrils were separated from soluble tau species by 
centrifugation at 16,000 g for 15 minutes. The fibrils were 
then resuspended in a tenth of the original volume in 0.05 M 
ammonium acetate pH 7 containing 1 mM DTT, vortexed for 
10 seconds and sonicated for 15 seconds in a water bath. Then 
10 µM seeds, 10 µM K18 ΔK280 tau and 0 µM, 0.5 µM, 2 
µM or 10 µM Hsp70 were combined in aggregation buffer 
containing 10 µM ThT and heparin in a microwell plate 
(Corning 96-well half area clear bottom). ThT kinetics were 
monitored in a plate reader as described above. To extract 
relative elongation rates from the recorded aggregation 
kinetics, the raw data was fitted as described in the supporting 
information.  
smFRET instrumentation and data acquisition. The 
confocal FRET instrument and the data acquisition have 
previously been described in detail17,25. 
SmFRET analysis of tau oligomerization. In order to study 
the oligomerization of tau, equimolar amounts of monomeric 
AF488-labeled ΔK280 tau and AF647-labeled ΔK280 tau 
were combined at a concentration of 10 µM in a 200 µl PCR 
tube at 4 °C. To test the effect of Hsp70 on the aggregation of 
tau, indicated amounts of the chaperone were added prior to 
the initiation of aggregation. To start the aggregation, heparin 
was added to the aggregation mixture. The first time point (t0) 
was measured before the addition of heparin. For smFRET 
analysis, samples were diluted into 0.05 M ammonium acetate 
pH 7 to a final protein concentration of 200 pM and the 
sample was flowed through the channel of a microfluidic 
device mounted on a confocal setup as described previously20. 
The data was analyzed as described previously17,25 and a 
summary can be found in the supporting information. 
Testing the binding of Hsp70 to tau by TIRF microscopy. 
To assess direct binding of Hsp70 to monomeric tau, 10 µM 
ΔK280 tau-AF488 was mixed with 2 µM Hsp70-AF405 in a 
200 µl PCR tube and the sample was incubated on ice for 10 
minutes. To assess the direct binding of Hsp70 to oligomeric 
tau, dual-labeled tau oligomers were produced as described 
above in presence of 2 µM Hsp70-AF405 in a 200 µl PCR 
tube. Then, samples were diluted into 0.05 M ammonium 
acetate pH 7 to a tau concentration of 50-200 pM, and 
adsorbed onto a glass cover slide for 15 minutes and imaged 
on a TIRF microscope using the appropriate illumination 
sources and emission filters.  
To test the binding of Hsp70 to fibrillar tau, unlabeled ΔK280 
tau was fibrillated as described above for 24 hours. This 
fibrillar sample was then incubated with 1.98 µM unlabeled 
Hsp70 and 0.02 µM Hsp70-AF405 for 10 minutes on ice. 
Finally, the sample was diluted to a tau concentration of 25 
nM into 0.05 M ammonium acetate pH 7 containing 30 nM of 
the fibrillar stain pFTAA, adsorbed onto a glass cover slide for 
15 minutes and visualized by TIRF microscopy using the 
appropriate illumination sources and emission filters. 
To control for bleed through and cross-excitation of 
fluorophores, identical samples were prepared where only one 
of the interaction partners was fluorescently labeled. Both 
bleed through and cross-excitation were negligible. 
The TIRF microscope and the binding stoichiometry analysis 
are described in the supporting information. 
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Measuring binding affinities of Hsp70 to tau by smFRET. 
Testing association and disassociation kinetics: see supporting 
information.  
Saturating binding curves. Tau oligomers or fibrils were 
prepared as described above. Notably, to remove any non-
fibrillar material, the fibrils were separated from soluble tau 
species by centrifugation at 16,000 g for 15 minutes. The 
fibrils were then resuspended in 45 µl 0.05 M ammonium 
acetate pH 7 containing 1 mM DTT, vortexed for 10 seconds 
and sonicated for 15 seconds in a water bath.  
To perform binding saturation experiments, 100 nM oligomers 
or 1,200 nM fibrils (initial monomer concentration) were 
mixed with increasing Hsp70 concentrations from 0.5 nM to 
10 µM and incubated for 5 minutes on ice. Then the sample 
was diluted to 200 pM tau concentration and the association 
was determined by smFRET (data analysis described in the 
supporting information). 
Lipid vesicles permeabilization assay. Tau samples were 
oligomerized as described above. The purification of lipid 
vesicles, their attachment onto glass coverslides and the TIRF 
microscope used for imaging are described in detail in Ref31. 
To test the effect of tau on the lipid vesicles, 50 µl of either i) 
10 nM tau monomers ii) 10 nM tau oligomers or iii) 10 nM tau 
oligomers plus Hsp70 (2 nM) were added onto the coverslip 
and incubated for 10 min. Importantly, glass coverslips were 
not moved during the addition of samples. Then images were 
acquired. Next, 10 µl of a solution containing 1 mg ml-1 of 
ionomycin (Cambridge Bioscience Ltd) was added and 
incubated for 5 min and subsequently images of Ca2+-saturated 
single vesicles in the same fields of view were acquired. 
Vesicles were visualized by TIRF microscopy using the 
appropriate illumination sources and emission filters. The 
recorded images were analyzed using ImageJ56 to determine 
the fluorescence intensity of each spot under the three 
different conditions, namely background (Fbackground), in the 
presence of a sample (Fsample), and after the addition of 
ionomycin (FIonomycin). The relative influx of Ca2+-ions due to 
the presence of the respective tau sample was then determined 
using the following equation: 
 Ca!! − influx = !!"#$%&!!!"#$%&'()*!!"#"$%&'#!!!"#$%   (1) 
Statistics. Statistical analysis was performed with OriginPro 
2016. One-way ANOVA followed by post-hoc Tukey test was 
used. Differences were considered to be significantly different 
if p < 0.05. 
SUPPORTING INFORMATION 
The Supporting Information is available free of charge via the 
internet at http://pubs.acs.org. This includes Figures S1-S4 and 
information on the association and disassociation kinetics of tau 
and Hsp70, the fitting process to obtain relative elongation rate 
constants and the data analysis of the single-molecule assays 
performed for this study.  
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